Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 811

1.

In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.

Elbeik T, Hoo BS, Campodonico ME, Dileanis J, Fay FF, Bortolozzi RL, Benetti MS, Fay OH, Marlowe N, Petrauskene O, Chernoff D, Smith L, Ng VL.

J Hum Virol. 2001 Nov-Dec;4(6):317-28.

PMID:
12082398
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
4.

Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.

Gallego O, de Mendoza C, Pérez-Elías MJ, Guardiola JM, Pedreira J, Dalmau D, Gónzalez J, Moreno A, Arribas JR, Rubio A, García-Arata I, Leal M, Domingo P, Soriano V.

AIDS. 2001 Sep 7;15(13):1701-6.

PMID:
11546946
5.

Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.

Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E.

AIDS. 2003 Jul;17 Suppl 3:S31-8.

PMID:
14565607
6.

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, Blanche S, Rouzioux C, Msellati P.

Pediatr Infect Dis J. 2005 Dec;24(12):1072-6.

PMID:
16371868
7.

Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M.

J Med Virol. 2003 Jan;69(1):1-6.

PMID:
12436471
8.

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.

Lafeuillade A, Poggi C, Hittinger G, Chadapaud S.

HIV Med. 2001 Oct;2(4):231-5.

9.
11.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
12.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
13.

Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.

Antivir Ther. 2000 Mar;5(1):7-14.

PMID:
10846586
14.

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.

Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.

AIDS. 1998 Jun 18;12(9):1015-20.

PMID:
9662197
15.

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.

Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A.

AIDS. 2002 May 3;16(7):1039-44.

PMID:
11953470
16.
17.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.

19.

Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.

Vignoles M, Barboni G, Agosti MR, Quarleri J, García MK, Ayala SG, Salomón H.

Antivir Ther. 2009;14(8):1175-81. doi: 10.3851/IMP1461.

PMID:
20032547
20.

Supplemental Content

Support Center